Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeanne Chiaravalli

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Iscience|June 17, 2024
High-throughput screening identifies broad-spectrum Coronavirus entry inhibitorsSuman Khan, Efrat Ozer Partuk, Jeanne Chiaravalli, et al.
International Journal of Antimicrobial Agents|January 2, 2021
Inhibition of the replication of SARS-CoV-2 in human cells by the FDA-approved drug chlorpromazineMarion Plaze, David Attali, Matthieu Prot, et al.
European Journal of Medicinal Chemistry|May 6, 2025
Design, synthesis, biophysical and biological evaluation of original condensed pyrrolopyrimidine and pyrrolopyridine ligands as anti-SARS-CoV-2 agents targeting G4Jean Guillon, Solène Savrimoutou, Nicolas Da Rocha, et al.
Molecular Cancer Therapeutics|December 17, 2014
Identification of novel radiosensitizers in a high-throughput, cell-based screen for DSB repair inhibitorsAlexander G Goglia, Robert Delsite, Antonio N Luz, et al.
Nature Microbiology|August 17, 2021
SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolutionJiří Zahradník, Shir Marciano, Maya Shemesh, et al.
Nature Communications|September 22, 2021
Characterising proteolysis during SARS-CoV-2 infection identifies viral cleavage sites and cellular targets with therapeutic potentialBjoern Meyer, Jeanne Chiaravalli, Stacy Gellenoncourt, et al.
Nature Communications|November 21, 2025
Targeting ACE2 with a camelid antibody inhibits SARS-CoV-2 binding and has protective effects in vivoSimon Blachier, Marie-Christine Vaney, Laurine Conquet, et al.
The Journal of Experimental Medicine|June 15, 2022
Potent human broadly SARS-CoV-2-neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2Cyril Planchais, Ignacio Fernández, Timothée Bruel, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Iscience|June 17, 2024
High-throughput screening identifies broad-spectrum Coronavirus entry inhibitorsSuman Khan, Efrat Ozer Partuk, Jeanne Chiaravalli, et al.
International Journal of Antimicrobial Agents|January 2, 2021
Inhibition of the replication of SARS-CoV-2 in human cells by the FDA-approved drug chlorpromazineMarion Plaze, David Attali, Matthieu Prot, et al.
European Journal of Medicinal Chemistry|May 6, 2025
Design, synthesis, biophysical and biological evaluation of original condensed pyrrolopyrimidine and pyrrolopyridine ligands as anti-SARS-CoV-2 agents targeting G4Jean Guillon, Solène Savrimoutou, Nicolas Da Rocha, et al.
Molecular Cancer Therapeutics|December 17, 2014
Identification of novel radiosensitizers in a high-throughput, cell-based screen for DSB repair inhibitorsAlexander G Goglia, Robert Delsite, Antonio N Luz, et al.
Nature Microbiology|August 17, 2021
SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolutionJiří Zahradník, Shir Marciano, Maya Shemesh, et al.
Nature Communications|September 22, 2021
Characterising proteolysis during SARS-CoV-2 infection identifies viral cleavage sites and cellular targets with therapeutic potentialBjoern Meyer, Jeanne Chiaravalli, Stacy Gellenoncourt, et al.
Nature Communications|November 21, 2025
Targeting ACE2 with a camelid antibody inhibits SARS-CoV-2 binding and has protective effects in vivoSimon Blachier, Marie-Christine Vaney, Laurine Conquet, et al.
The Journal of Experimental Medicine|June 15, 2022
Potent human broadly SARS-CoV-2-neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2Cyril Planchais, Ignacio Fernández, Timothée Bruel, et al.
Pageof 2